Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
2
0
4

Year Published

2018
2018
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(7 citation statements)
references
References 23 publications
1
2
0
4
Order By: Relevance
“…A frequently cited randomised controlled trial 23 of nine-valent PCV done in The Gambia in the early 2000s found, in a post-hoc analysis, that the vaccine reduced all-cause childhood mortality by 16%—a far broader endpoint and, thus, a much larger benefit than the reduction that WHO states could be achieved in pneumonia mortality alone. Estimates from the handful of published post-introduction studies of the effect of PCV use on childhood pneumonia mortality are variable, although the benefits are generally larger than those we found in Brazil; one study from Brazil 24 reported no benefit, whereas another from Chile 25 estimated an extraordinarily large benefit (table 2).…”
Section: Discussionmentioning
confidence: 53%
“…A frequently cited randomised controlled trial 23 of nine-valent PCV done in The Gambia in the early 2000s found, in a post-hoc analysis, that the vaccine reduced all-cause childhood mortality by 16%—a far broader endpoint and, thus, a much larger benefit than the reduction that WHO states could be achieved in pneumonia mortality alone. Estimates from the handful of published post-introduction studies of the effect of PCV use on childhood pneumonia mortality are variable, although the benefits are generally larger than those we found in Brazil; one study from Brazil 24 reported no benefit, whereas another from Chile 25 estimated an extraordinarily large benefit (table 2).…”
Section: Discussionmentioning
confidence: 53%
“…Our observational study contributes to a surprisingly small body of post-introduction studies of the effect of PCV use on childhood pneumonia mortality ( Table 3). The handful of published studies reported either no overall mortality benefit (24) or mortality benefits larger than what could reasonably be expected based on estimates of pneumonia mortality burden. At the high end, a study set in Chile reported a decline of 35% (9-54%) in mortality from all causes after PCV10 introduction in 3-23 month olds (25)-even though pneumonia deaths contributed only ~8% of all deaths in Chile in 2010 (11).…”
Section: Discussionmentioning
confidence: 96%
“…Kupek e Vieira (2016) (37) Avaliar o impacto da vacina pneumocócica PCV10 na redução da mortalidade por pneumonia em crianças menores de um ano, em Santa Catarina.…”
Section: Estudo Analítico Transversal/ Necunclassified